The United Kingdom and the United States have agreed to a landmark trade agreement that will keep no levies on British medicine shipments going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to increase spending on pharmaceuticals through the public health system. This pledge secures that tariffs on these crucial products will remain at zero for a timeframe of the next three years.
This deal follows recent statements to dramatically increase duties on branded pharmaceutical imports, with figures floated up to double the cost.
"This deal between the United Kingdom bolsters the worldwide climate for new treatments and establishes much-needed equity to transatlantic pharmaceutical trade," a statement said.
Economic Impact
Medicines are one of the the United Kingdom's most significant export categories to the US, which is clearly the primary destination for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of September, the UK exported medicines worth billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This agreement safeguards work, increases funding and facilitates the UK to emerge as a worldwide center for life sciences," a minister commented.
Detailed NHS Changes
The agreement includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than twenty percent.
Industry Background
The deal follows a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were exacerbated by assertions that US customers were charged several times more for the identical medicines than patients in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been paused or abandoned, while substantial investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
